Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2016 - 2025)

Zevra Therapeutics' Net Income towards Common Stockholders history spans 11 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 134.04% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $83.2 million, up 178.88%, while the annual FY2025 figure was $83.2 million, 178.88% up from the prior year.
  • Net Income towards Common Stockholders reached $12.2 million in Q4 2025 per ZVRA's latest filing, up from -$544000.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $74.7 million in Q2 2025 to a low of -$47.7 million in Q1 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$8.6 million, with a median of -$9.7 million recorded in 2022.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 1345.05% in 2021, then surged 474.94% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$2.7 million in 2021, then plummeted by 233.74% to -$9.0 million in 2022, then plummeted by 120.51% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Net Income towards Common Stockholders are $12.2 million (Q4 2025), -$544000.0 (Q3 2025), and $74.7 million (Q2 2025).